id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-E-6604-0008,FDA,FDA-2017-E-6604,"Determination of Regulatory Review Period for Purposes of Patent
Extension; KEVZARA",Notice,Determinations,2018-11-30T05:00:00Z,2018,11,2018-11-30T05:00:00Z,2019-01-30T04:59:59Z,2018-11-30T15:50:45Z,2018-26033,0,0,09000064839161bb
FDA-2017-E-6604-0007,FDA,FDA-2017-E-6604,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-11-20T05:00:00Z,2018,11,2018-11-20T05:00:00Z,,2018-11-20T13:40:58Z,,0,0,09000064838ec391
FDA-2017-E-6604-0006,FDA,FDA-2017-E-6604,Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2018-09-27T04:00:00Z,2018,9,2018-09-27T04:00:00Z,,2018-09-27T16:50:04Z,,0,0,090000648377c85f
FDA-2017-E-6604-0005,FDA,FDA-2017-E-6604,Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2018-09-27T04:00:00Z,2018,9,2018-09-27T04:00:00Z,,2018-09-27T16:47:42Z,,0,0,090000648377b01d
FDA-2017-E-6604-0004,FDA,FDA-2017-E-6604,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2018-04-24T04:00:00Z,2018,4,2018-04-24T04:00:00Z,,2018-04-24T14:28:51Z,,0,0,09000064831b8ed7
FDA-2017-E-6604-0003,FDA,FDA-2017-E-6604,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2018-02-06T05:00:00Z,2018,2,2018-02-06T05:00:00Z,,2018-02-06T20:08:14Z,,0,0,0900006482ef43cc